Catheter Improves 89-Year-Old Woman's Calcified Aortic Valve
CoreValve announced that its patented ReValving System, consisting of a 18F delivery catheter, was used to percutaneously implant its proprietary porcine pericardial-tissue bioprosthesis over the severely calcified aortic heart valve of an 89-year-old woman. In contrast to long post-surgical recuperation times, this PAVR patient was discharged from the ICU to the general ward on the morning after her ReValving procedure and was fully mobile and awaiting discharge from the hospital.
The successful procedure was performed at Erasmus University Medical Center, Rotterdam, The Netherlands, by Professor Patrick W. Serruys and Dr. Peter DeJaegere, globally recognized interventional cardiologists who have been leading investigators in clinical trials of numerous cutting-edge technologies.
More like this
- Rapid Enrollment Proceeds for Aortic “Revalving”
- Successful CoreValve Implants Represent Medical Milestones
- First Cases Completed in Australia, New Zealand Using ReValving System for Percutaneous Aortic Valve Replacement
- First Cath Lab-Based Device for Aortic Valve Replacement Approved in Europe
- Percutaneous ReValving System Faces Clinical Evaluation in Australia/New Zealand



